ADNI data is made available to researchers around the world. As such, there are many active research projects accessing and applying the shared ADNI data. To further encourage Alzheimer’s disease research collaboration, and to help prevent duplicate efforts, the list below shows the specific research focus of the active ADNI investigations. This information is requested annually as a requirement for data access.
|Principal Investigator's Name:||Reema Ganotra|
|Department:||Department of Electronics|
|Proposed Analysis:||EARLY DETECTION OF ALZHEIMER DISEASE USING MAGNETIC RESONANCE IMAGING AS BIOMARKER Dementia is loss of memory characterized by impairments in mental functions. These impairments are so severe that the person with dementia is totally dependent on others for every single task. Alzhiemer’s disease is the most common type of dementia. It is a group of deformation in brain that impairs mental functioning such as cognition and language. Alzhiemer’s disease is incurable and progressive disease. The time course and symptoms of the disease varies from person to person. Amyloid plaques and neurofibrillary tangles are prime suspects of Alzhiemer’s disease. Plaques are composed of Beta-amyloid protein and cellular material which get deposited on outside and around a nerve cell. Tangles are made up of abnormal tau-protein .They are in twisted form and are present inside a nerve cell. Many scientists thought that the deposition of amyloid in the form of plaques triggers the disorders that lead to Alzhiemer’s disease. Scientist believe that plaques and tangles obstruct the communication among nerve cells and block the process like neurotransmission and chemical messaging that they need to survive. The early stages of Alzhiemer’s disease are recognised as mild cognitive impairment (MCI). All patients with MCI may or may not develop Alzhiemer’s disease, but they are always at high risk. Plaques and tangles get develop in quite predictable manner for e.g. Loss of memory is the first symptom of Alzhiemer’s disease and long term memory is concerned with hippocampus. So it is possible to detect whether a person with MCI will develop Alzhiemer’s disease or not in later stages, well before first symptom of disease appears. With reference to various paper published in last ten years it can be assumed that atrophy of temporal lobe specially hippocampus and entorihnal cortex is a sensitive indicator of Alzhiemer’s disease. Studies have demonstrated that patients with atrophy in entorhinal cortex developed Alzhiemer’s disease with accuracy of 84% and with that of hippocampus developed Alzhiemer’s disease up to 80%-90%. So MRI imaging of hippocampus and entorhinal cortex and their analysis after comparison with healthy patient’s MRI can perform as a useful biomarker in early detection of Alzhiemer’s disease. In this project I am going for early detection of Alzhiemer’s disease with the help of MRI as biomarker.|